Narcolepsy is a devastating, neurological condition characterized by excessive daytime sleepiness (EDS), the most common presenting symptom, as well as cataplexy, hypnagogic hallucinations, and sleep paralysis. Though recent practice guidelines have been released, these guidelines do not include recent U.S. Food and Drug Administration (FDA) approvals with strategies to lower sodium, which may be an ideal treatment option in patients with cardiovascular (CV) comorbidities or risk factors. As patients with narcolepsy often experience residual EDS despite traditional treatment, it is imperative that health care professionals (HCPs) possess the knowledge to identify EDS and skills to integrate effective novel therapies to achieve sustained benefits to optimize patient outcomes.
Join Drs. Bogan, Thorpy, and Weaver for an OnDemand symposium as they discuss evidence-based strategies to reduce EDS and cataplexy, among other symptoms, and restore quality of life and functioning in patients with narcolepsy.
At the end of this CME/CE activity, participants should be able to:
Supported by an educational grant from Jazz Pharmaceuticals, Inc.
Physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in sleep medicine, psychiatry, neurology, pulmonology and/or primary care
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Bogan reports the following financial relationships: Consultant: Harmony Biosciences, LLC; Jazz Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc. Grants: Axsome Therapeutics, Inc.; Eisai Inc.; Flamel Technologies; Fresca Medical, Inc.; Harmony Biosciences, LLC; Idorsia Pharmaceuticals; Jazz Pharmaceuticals, Inc.; Merck & Co., Inc.; Philips; Suven Life Sciences; and Takeda Pharmaceuticals U.S.A., Inc. Speakers Bureau: Eisai Inc.; Harmony Biosciences, LLC; and Jazz Pharmaceuticals, Inc.
Ms. Flygare reports the following financial relationships: Consultant: Orexia Therapeutics and Takeda Pharmaceutical Company Limited
Dr. Thorpy reports the following financial relationships: Advisory Board and Consultant: Axsome Therapeutics, Inc.; Balance Therapeutics; Eisai Inc.; Flamel Technologies/Avadel; Harmony Biosciences, LLC; Jazz Pharmaceuticals, Inc.; NLS Pharmaceutics; Suven Life Sciences Limited; Takeda Pharmaceutical Company Limited; and XWPharma
Dr. Weaver reports the following financial relationships: Advisory Board: Idorsia Pharmaceuticals Alliance for Sleep; Consultant: Bayer and Eli Lilly and Company; Other Financial Support: Axsome Therapeutics, Inc.; Bayer AG; Clinical Outcomes Solutions; Cook Medical; Eli Lilly and Company; Functional Outcomes of Sleep Questionnaire (FOSQ); Harmony Biosciences, LLC; Jazz Pharmaceuticals, Inc.; LivaNova PLC; Nyxoah; Philips Respironics; ResMed; ResMed Germany; RWS; Signant Health; Signifier Medical Technologies; Stratevi; Valis Biosciences Inc.; and Verily Life Sciences
The following peer reviewer and CME Outfitters staff report no financial relationships:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Available as a webcast with resources or video only
NOTE: Pharmacist CE Universal Activity Number, Enduring: JA0007185-0000-22-066-H01-P.
Call us at 877.CME.PROS (877.263.7767).